Nonetheless, this study represents a meaningful advancement towards the clinical translation of ddPCR-based BRCA1/2 CNV detection, and these integrated tools may ultimately support the development of clinically actionable CNV biomarkers in prostate cancer and other malignancies. This evidence concerns the gene BRCA1 and Familial prostate cancer.